Amarin AMRN
Amarin Q2 FY24: revenue $67.5M; diluted EPS $0.00
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-088233
- Document
- 10-Q
Key figures from this report
These are the numbers Amarin reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$67.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income$1.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS$0.00No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$215.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$2.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
- Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025
- Usana Health Sciences USNA public float $328M, Jun 27, 2025
- Emergent BioSolutions EBS public float $343M, Jun 30, 2025
- Altimmune ALT public float $327M, Jun 30, 2025
